Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL3545132

MIRVETUXIMAB SORAVTANSINE
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL3545132
Name MIRVETUXIMAB SORAVTANSINE
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Elahere IMGN-853 IMGN853 Mirvetuximab soravtansina Mirvetuximab soravtansine Mirvetuximab soravtansine gynx Mirvetuximab soravtansine-gynx
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
7
Known Names
7
Indications
2
Mechanisms

Drug Information

Molecule Type Antibody drug conjugate
First Approval 2022
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

Black Box Warning First in Class
USAN Stem -mab; -tansine
USAN Year 2015

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Folate receptor alpha binding agent BINDING AGENT Folate receptor alpha ✓ ✓
Tubulin inhibitor INHIBITOR Tubulin ✓ ✓

Indications

Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms Neoplasms Peritoneal Neoplasms Endometrial Neoplasms Triple Negative Breast Neoplasms Breast Neoplasms

ATC Classification

L01FX26
mirvetuximab soravtansine
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS

Drug Warnings

Black Box Warning
General Warning
Country: United States

Data from ChEMBL 36 via Core Engine